Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients

Clinical Cancer Research

Volumn 22, Issue 8, 2016, Pages 1914-1921

  Curti, Antonio ^a   Ruggeri, Loredana ^b   Parisi, Sarah ^a   Bontadini, Andrea ^a   Dan, Elisa ^a   Motta, Maria Rosa ^a   Rizzi, Simonetta ^a   Trabanelli, Sara ^a   Ocadlikova, Darina ^e   Lecciso, Mariangela ^a   Giudice, Valeria ^a   Fruet, Fiorenza ^a   Urbani, Elena ^b   Papayannidis, Cristina ^a   Martinelli, Giovanni ^a   Bandini, Giuseppe ^a   Bonifazi, Francesca ^a   Lewis, Russell E ^c   Cavo, Michele ^a   Velardi, Andrea ^b   Lemoli, Roberto M ^d   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; INTERLEUKIN 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; ALLOANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; APPLICATION SITE ERYTHEMA; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HAPLOIDY; HUMAN; HUMAN CELL; LEUKEMIA RELAPSE; MALE; MIDDLE AGED; NATURAL KILLER CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYREXIA IDIOPATHICA; SIDE EFFECT; ADVERSE EFFECTS; AGE; CLINICAL TRIAL; DONOR; GENETICS; GENOTYPE; HAPLOTYPE; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PROCEDURES; RECURRENT DISEASE; TREATMENT OUTCOME;

AGE FACTORS; AGED; COMBINED MODALITY THERAPY; FEMALE; GENOTYPE; HAPLOTYPES; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; ISOANTIGENS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PHENOTYPE; PROSPECTIVE STUDIES; RECEPTORS, KIR3DL1; RECURRENCE; TISSUE DONORS; TREATMENT OUTCOME;

EID: 84966769819     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1604     Document Type: Article

References (26)

1. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-62.
2. Ofran Y, Rowe JM. Genetic profiling in acute myeloid leukaemia-where are we and what is its role in patient management. Br J Haematol 2013; 160:303-20.
3. Farag SS, Caligiuri MA. Humannatural killer cell development and biology. Blood 2006;20:123-37.
4. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008;27:5932-43.
5. Höglund P, Brodin P. Current perspectives of natural killer cell education by MHC class I molecules. Nat Rev Immunol 2010;10:724-34.
6. Moretta L, Moretta A. Killer immunoglobulin-like receptors. Curr Opin Immunol 2004;16:626-33.
7. Moretta A, Locatelli F, Moretta L. HumanNK cells: fromHLA class I-specific killer Ig-like receptors to the therapy of acute leukemias. Immunol Rev 2008;224:58-69.
8. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999;94:333-9.
9. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-100.
10. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, et al. Donor natural killer cell allorecognition ofmissing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007;110:433-40.
11. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and re-definition of inhibitory KIR specificity. Blood 2008;113:3119-29.
12. Willemze R, Rodrigues CA, Labopin M, Sanz G, Michel G, Socié G, et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009;23:492-500.
13. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, et al.et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003;102:814-9.
14. Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS, et al.et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002;100:3825-7.
15. Bornhäuser M, Schwerdtfeger R, Martin H, Frank KH, Theuser C, Ehninger G. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 2004;103:2860-1.
16. Hsu KC, Gooley T, Malkki M, Pinto-Agnello C, Dupont B, Bignon JD, et al. et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006;12:828-36.
17. Malmberg KJ, Schaffer M, Ringdén O, Remberger M, Ljunggren HG. KIRligand mismatch in allogeneic hematopoietic stem cell transplantation. Mol Immunol 2005;42:531-4.
18. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, et al.et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010;116:2411-9.
19. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105: 3051-7.
20. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010;28:955-9.
21. Curti A, Ruggeri L, D'Addio A, Bontadini A, Dan E, Motta MR, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acutemyeloid leukemia patients. Blood 2011;118:3273-9.
22. Bontadini A, Testi M, Cuccia MC, Martinetti M, Carcassi C, Chiesa A, et al. Distribution of killer cell immunoglobulin-like receptors genes in the Italian Caucasian population. J Transl Med 2006;4:44-52.
23. Kristt D, Gesundheit B, Stein J, Shapira MY, Or R, Amar A, et al. Quantitative monitoring of multi-donor chimerism: A systematic, validated framework for routine analysis. Bone Marrow Transplant 2010;45:137-47.
24. Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 2014;123:3855-63.
25. De Santis D, Foley BA, John E, Senitzer D, Christiansen FT, Witt CS. Rapid, flow cytometric assay for NK alloreactivity reveals exceptions to rules governing alloreactivity. Biol Blood Marrow Transplant 2010;16:179-91
26. Fauriat C, Andersson S, Bjorklund AT, Carlsten M, Schaffer M, Bjorkstrom NK, et al. Estimation of the size of the alloreactiveNKcell repertoire: studies in individuals homozygous for the group A KIR haplotype. J Immunol 2008;181:6010-9.